Analyst Sees Over 160% Upside for IntelliPharmaCeutics Intl Inc (USA) Stock

It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success …

Stock Update (NASDAQ:IPCI): IntelliPharmaCeutics Announces First Quarter 2016 Results

Intellipharmaceutics International Inc. (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage …

Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals

hares of IntelliPharmaceutics International  (NASDAQ: IPCI) saw a nearly 6% increase in trading on Tuesday, February 2nd following the company’s announcement that it has signed …

IPCI’s Novel Overdose Deterrence Technology Blows Us Away, Says Maxim

In a research report released September 5, Maxim Group analyst Jason Kolbert upgraded shares of IntelliPharmaCeutics (NASDAQ:IPCI) from Hold to Buy rating and raised his price target to $7.00 (from $3.

IntelliPharmaCeutics: We See No Reason To Be Long On Shares, Says Maxim

In a research report released July 21, Maxim Group analyst Jason Kolbert reaffirmed a Hold rating on IntelliPharmaCeutics (IPCI) with a $3 price target.  The analyst commented: “IPCI reported the quarter last …

Maxim Group Downgrades Intellipharmaceutics To Hold, Lowers PT to $3

In a research report issued today, IntelliPharmaCeutics International Inc. (IPCI) was downgraded by analyst Jason Kolbert at Maxim Group from Buy to Hold.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts